Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research note released on Wednesday morning. The firm issued a buy rating on the biotechnology company’s stock.

Separately, Barclays reduced their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Trading Down 2.2 %

NASDAQ:CLLS opened at $1.54 on Wednesday. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $85.59 million, a price-to-earnings ratio of -1.18 and a beta of 3.06. The firm has a fifty day simple moving average of $1.64 and a two-hundred day simple moving average of $1.91. Cellectis has a 12 month low of $1.41 and a 12 month high of $3.38.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Millennium Management LLC purchased a new position in Cellectis during the fourth quarter worth about $962,000. B Group Inc. purchased a new position in Cellectis during the fourth quarter worth about $5,547,000. Finally, Wells Fargo & Company MN boosted its holdings in Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 12,500 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.